Incyte Corp (NASDAQ:INCY)

fda_logo

5 Critical Biotech Drug Dates and Events for December

At least five upcoming dates could be big days in December, for better or worse, for individual biotech stocks. These events refer to reviews and decisions by the U.S. Food ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Aegerion, Avon, Atmel, LinkedIn, Ocwen, Visa and More

Stocks screamed higher on Friday on a surprise Japan expansion of its own stimulus and quantitative easing measures. Investors have proved, even during October, that they are willing to buy ...
Read Full Story »
biotech

Analyst Sees Incyte Worth 70% More

Incyte Corp. (NASDAQ: INCY) has serious upside potential, but the inherent risk within it may be too much for some investors to bear. This stock is not for the risk ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: AEP, BHP, GE, Incyte, 3M, Tyco, Under Armour and More

Stocks were firm on Wednesday morning ahead of the FOMC meeting outcome. Tuesday's rally may have sparked higher interest again, and investors are looking for bargains now that stocks are still ...
Read Full Story »
Biotechnology word cloud

SunTrust Robinson Humphrey Starts Coverage on 5 Top Biotech Stocks

The firms we cover on Wall Street are sometimes like covering the major sports teams. Analysts are like the top players and tend to move around as their career strengths ...
Read Full Story »
Biotechnology word cloud

UBS Very Bullish on Biotech Stocks Ahead of Second-Quarter Earnings

After the biotech stocks were absolutely crushed in the late winter and early spring, many of the top firms we cover on Wall Street were aggressive in their calls to ...
Read Full Story »
research

Three Companies That Want to Cure Pancreatic Cancer

Within 20 years cancer is expected to be the number one killer of people in the United States. While many cancers are survivable with chemotherapy and radiation, one that ...
Read Full Story »
DNA

Top Biotech Stocks for Cancer Cures From Cowen

The conference season is starting to get into full swing, and for the top biotech stocks, that means an appearance at the American Society of Clinical Oncology yearly conference. Many ...
Read Full Story »
investor research

Top Analyst Upgrades and Downgrades: Buffalo Wild Wings, Coca-Cola, DSW, Intuitive Surgical and More

As earnings season continues to roll on, investors are keeping a close eye not only on the final results for the first quarter, but how those results are being interpreted. ...
Read Full Story »
DNA

UBS Top Stocks to Buy Working for Cancer Cures

Cancer is the leading cause of death globally, and a disease that touches almost every person in our nation one way or another. In a new research report, the Healthcare ...
Read Full Story »
DNA

J.P. Morgan’s Top Biotech and Health Care Picks With Huge Upside

Since March 4, the biotech index is off a massive 19%. There has been plenty of Wall Street speculation on why the sell-off was so violent, but at the end ...
Read Full Story »
Pills

Jefferies Biotech Stocks to Buy With Breakthrough Drug Innovations

New drug innovations are affecting the way that physicians treat such debilitating and deadly diseases as cancer. In a new research report, Jefferies presents the top drug innovations that investors ...
Read Full Story »
Monkey evil

Top Analyst Upgrades and Downgrades: LinkedIn, Safeway, NII Holdings, Rangold, EP Energy and More

Stocks are challenging new highs again and earnings season is just about over. Investors are carefully deciding how to position themselves for gains ahead and to avoid the next serious sell-off. ...
Read Full Story »
Biotechnology word cloud

Short Sellers Shy Away From Biotechs

24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. By and large, short sellers shied away from these stocks in late January. The largest ...
Read Full Story »
pills

Merck Earnings Fail to Dazzle, but the Company’s Story Remains Strong

Drug giant Merck & Co. Inc. (NYSE: MRK) reported fourth-quarter and full-year 2013 results before markets opened Wednesday morning. The company reported quarterly adjusted diluted earnings per share (EPS) of ...
Read Full Story »